AU683459B2 - Compositions and methods for the treatment of immunomediated inflammatory disorders - Google Patents

Compositions and methods for the treatment of immunomediated inflammatory disorders Download PDF

Info

Publication number
AU683459B2
AU683459B2 AU63647/94A AU6364794A AU683459B2 AU 683459 B2 AU683459 B2 AU 683459B2 AU 63647/94 A AU63647/94 A AU 63647/94A AU 6364794 A AU6364794 A AU 6364794A AU 683459 B2 AU683459 B2 AU 683459B2
Authority
AU
Australia
Prior art keywords
hydrogen
integer
hydroxy
naphthyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU63647/94A
Other languages
English (en)
Other versions
AU6364794A (en
Inventor
Heinz W Gschwend
Charles Johnson
Kerry Spear
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axys Pharmaceuticals Inc
Original Assignee
Arris Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharmaceutical Corp filed Critical Arris Pharmaceutical Corp
Publication of AU6364794A publication Critical patent/AU6364794A/en
Application granted granted Critical
Publication of AU683459B2 publication Critical patent/AU683459B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU63647/94A 1993-03-12 1994-03-11 Compositions and methods for the treatment of immunomediated inflammatory disorders Ceased AU683459B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3077093A 1993-03-12 1993-03-12
US3118793A 1993-03-12 1993-03-12
US031187 1993-03-12
US030770 1993-03-12
PCT/US1994/002706 WO1994020527A1 (en) 1993-03-12 1994-03-11 Compositions and methods for the treatment of immunomediated inflammatory disorders

Publications (2)

Publication Number Publication Date
AU6364794A AU6364794A (en) 1994-09-26
AU683459B2 true AU683459B2 (en) 1997-11-13

Family

ID=26706445

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63647/94A Ceased AU683459B2 (en) 1993-03-12 1994-03-11 Compositions and methods for the treatment of immunomediated inflammatory disorders

Country Status (11)

Country Link
EP (1) EP0688337A1 (uk)
JP (1) JPH08507768A (uk)
KR (1) KR100309616B1 (uk)
CN (2) CN1057772C (uk)
AU (1) AU683459B2 (uk)
CZ (1) CZ289930B6 (uk)
FI (1) FI954245A (uk)
PL (1) PL176941B1 (uk)
SK (1) SK282537B6 (uk)
UA (1) UA42719C2 (uk)
WO (1) WO1994020527A1 (uk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0763016B1 (en) * 1994-06-01 2000-01-26 Axys Pharmaceuticals, Inc. Compositions and methods for treating mast-cell mediated conditions
JPH10506390A (ja) 1994-09-23 1998-06-23 アリス ファーマシューティカル コーポレイション マスト細胞炎症症状を処置するための組成物及び方法
KR20000005312A (ko) 1996-04-10 2000-01-25 오노 야꾸힝 고교 가부시키가이샤 트립타아제 억제제 및 신규 구아니디노 유도체
CZ29799A3 (cs) * 1996-07-30 1999-06-16 Arris Pharmaceutical Corporation Disubstituovaná cyklická sloučenina, způsob její výroby, farmaceutický přípravek a způsob léčení onemocnění živočicha
WO1998024886A1 (en) * 1996-12-04 1998-06-11 Brigham And Women's Hospital, Inc. Mast cell protease that cleaves fibrinogen
US5955431A (en) * 1997-02-05 1999-09-21 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
US6221914B1 (en) * 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
AU1208999A (en) * 1997-11-10 1999-05-31 Array Biopharma, Inc. Compounds which inhibit tryptase activity
AU1176299A (en) * 1997-11-26 1999-06-15 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitors comprising heterocyclic amide compounds
SE9800729L (sv) * 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
SE515982C2 (sv) * 1998-03-06 2001-11-05 Lipocore Holding Ab Användning av en olja-i-vatten emulsion som bärare för framställning av en topikal kräm eller lotion
DE19939910A1 (de) * 1999-08-23 2001-03-01 Morphochem Ag Neue Verbindungen, die Tryptase-Aktivität hemmen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201863A (en) * 1974-11-08 1980-05-06 Mitsubishi Chemical Industries, Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4456595A (en) * 1982-12-06 1984-06-26 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy aroly peptides

Also Published As

Publication number Publication date
SK282537B6 (sk) 2002-10-08
FI954245A (fi) 1995-09-28
PL310559A1 (en) 1995-12-27
CZ289930B6 (cs) 2002-04-17
CN1234229A (zh) 1999-11-10
PL176941B1 (pl) 1999-08-31
UA42719C2 (uk) 2001-11-15
CZ232195A3 (en) 1996-07-17
KR100309616B1 (ko) 2002-02-28
FI954245A0 (fi) 1995-09-11
EP0688337A1 (en) 1995-12-27
WO1994020527A1 (en) 1994-09-15
CN1057772C (zh) 2000-10-25
CN1119019A (zh) 1996-03-20
AU6364794A (en) 1994-09-26
JPH08507768A (ja) 1996-08-20
SK112995A3 (en) 1996-10-02

Similar Documents

Publication Publication Date Title
US5525623A (en) Compositions and methods for the treatment of immunomediated inflammatory disorders
AU683459B2 (en) Compositions and methods for the treatment of immunomediated inflammatory disorders
RU2159229C2 (ru) Производные циклоалкилена или гетероциклоалкилена, фармацевтическая композиция, аэрозольное устройство и способ лечения
KR100339456B1 (ko) 신규펩티드유도체
EP0763016B1 (en) Compositions and methods for treating mast-cell mediated conditions
HU226979B1 (en) Bicyclic lactam inhibitor of interleukin-1-beta converting enzyme and pharmaceutical compositions containing them
JPH05504775A (ja) トロンビンの阻害剤および基質
JP2003524001A (ja) 新規マロン酸誘導体、それらの製造法、第Ｘａ因子活性の抑制剤としてのそれらの使用、およびそれらを含有する医薬組成物
JPS61189298A (ja) 新規オリゴペプチジルアルギニノール誘導体
US6355460B1 (en) Metal mediated serine protease inhibitors
WO1999024407A1 (en) Compounds which inhibit tryptase activity
US6362216B1 (en) Compounds which inhibit tryptase activity
US6566493B1 (en) Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
JP2003505008A (ja) α−ケトヘテロ環類を含有するセリンプロテアーゼ阻害剤
EP0298135A1 (en) Phenylalanine derivative and proteinase inhibitor
CZ20021424A3 (cs) Derivát hydroxamové kyseliny jako inhibitor tvorby rozpustné lidské CD23
WO1998022125A9 (en) Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
JPS63238051A (ja) フエニルアラニン誘導体および蛋白分解酵素阻害剤
KR20040062942A (ko) 파종성혈관내응고를 치료하기 위한 펩티드 아르기날 및 방법
JPS61218565A (ja) リジン誘導体及び抗プラスミン剤

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired